Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to Nutlin-3 induces a characteristic gene expression profile, which correlates with Nutlin-3-mediated cytotoxicity

Current Cancer Drug Targets

Volumn 9, Issue 4, 2009, Pages 510-518

  Zauli, G ^a   Di Iasio, M G ^a   Secchiero, P ^a   Dal Bo, M ^b   Marconi, D ^b   Bomben, R ^b   Del Poeta, G ^c   Gattei, V ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

B CLL; Gene expression profile; MDM2; Nutlin 3; p53 pathway

Indexed keywords

COMPLEMENTARY DNA; NUTLIN 3; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; DRUG EFFECT; DRUG MECHANISM; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; NUCLEOTIDE SEQUENCE; PROTEIN INDUCTION; WESTERN BLOTTING;

CELL DEATH; CELLS, CULTURED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67649366638     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909788486777     Document Type: Article

References (39)

1. Reed, J. C.; Kitada, S.; Kim, Y.; Byrd, J. Modulating apoptosis pathways in low grade B-cell malignancies using biological response modifiers. Semin. Oncol. 2002, 29, 10-24. (Pubitemid 34171790)
2. Dighiero, G.; Binet, J. L. When and how to treat chronic lymphocytic leukemia. N. Engl. J. Med. 2000, 343, 1799-1801.
3. Wierda, W.; O'Brien, S.; Wen, S.; Faderl, S.; Garcia-Manero, G.; Thomas, D.; Do, K. A.; Cortes, J.; Koller, C.; Beran, M.; Ferrajoli, A.; Giles, F.; Lerner, S.; Albitar, M.; Kantarjian, H.; Keating, M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2005, 23, 4070-4078. (Pubitemid 46211312)
4. Keating, M. J.; O'Brien, S.; Albitar, M.; Lerner, S.; Plunkett, W.; Giles, F.; Andreeff, M.; Cortes, J.; Faderl, S.; Thomas, D.; Koller, C.; Wierda, W.; Detry, M. A.; Lynn, A.; Kantarjian, H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2005, 23, 4079-4088. (Pubitemid 46211313)
5. Byrd, J. C.; Rai, K.; Peterson, B. L.; Appelbaum, F. R.; Morrison, V. A.; Kolitz, J. E.; Shepherd, L.; Hines, J. D.; Schiffer, C. A.; Larson, R. A. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105, 49-53. (Pubitemid 40053062)
6. Vassilev, L. T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 2007, 13, 23-31. (Pubitemid 46027725)
7. Deng, J.; Dayam, R.; Neamati, N. Patented small molecule inhibitors of p53-MDM2 interaction. Expert Opin. Ther. Pat. 2006, 16, 165-188. (Pubitemid 43263239)
8. Vassilev L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848. (Pubitemid 38174664)
9. Gaidano, G.; Ballerini, P.; Gong, J. Z.; Inghirami, G.; Neri, A.; Newcomb, E. W.; Magrath, I. T.; Knowles, D. M.; Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1991, 88, 5413-5417. (Pubitemid 21914755)
10. Wattel, E.; Preudhomme, C.; Hecquet, B.; Vanrumbeke, M.; Quesnel, B.; Dervite, I.; Morel, P.; Fenaux, P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84, 3148-3157. (Pubitemid 2153854)
11. Dohner, H.; Fischer, K.; Bentz, M.; Hansen, K.; Benner, A.; Cabot, G.; Diehl, D.; Schlenk, R.; Coy, J.; Stilgenbauer, S. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995, 85, 1580-1589.
12. Cordone, I.; Masi, S.; Mauro, F. R.; Soddu, S.; Morsilli, O.; Valentini, T.; Vegna, M. L.; Guglielmi, C.; Mancini, F.; Giuliacci, S.; Sacchi, A.; Mandelli, F.; Foa, R. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998, 91, 4342-4349. (Pubitemid 28261999)
13. Grever, M. R.; Lucas, D. M.; Dewald, G. W.; Neuberg, D. S.; Reed, J. C.; Kitada, S.; Flinn, I. W.; Tallman, M. S.; Appelbaum, F. R.; Larson, R. A.; Paietta, E.; Jelinek, D. F.; Gribben, J. G.; Byrd, J. C. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J. Clin. Oncol. 2007, 25, 799-804. (Pubitemid 350010635)
14. Secchiero, P.; Barbarotto, E.; Tiribelli, M.; Zerbinati, C.; di Iasio, M. G.; Gonelli, A.; Cavazzini, F.; Campioni, D.; Fanin, R., Cuneo, A.; Zauli, G. Functional integrity of the p53 mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107, 4122-4129. (Pubitemid 43726822)
15. Coll-Mulet, L.; Iglesias-Serret, D.; Santidrian, A. F.; Cosialls, A. M.; de Frias, M.; Castaño, E.; Campàs, C.; Barragán, M.; de Sevilla, A. F.; Domingo, A.; Vassilev, L. T.; Pons, G.; Gil, J. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006, 107, 4109-4114. (Pubitemid 43726820)
16. Kojima, K.; Konopleva, M.; McQueen, T.; O'Brien, S.; Plunkett, W.; Andreeff, M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006, 108, 993-1000. (Pubitemid 44154636)
17. Saddler, C.; Ouillette, P.; Kujawski, L.; Shangary, S.; Talpaz, M.; Kaminski, M.; Erba, H.; Shedden, K.; Wang, S.; Malek, S. N. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008, 111, 1584-1593. (Pubitemid 351213449)
18. Secchiero, P.; Melloni, E.; Tiribelli, M.; Zauli, G. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. J. Leukoc. Biol. 2008, 83, 434-437. (Pubitemid 351225625)
19. Secchiero, P.; Melloni, E.; Heikinheimo, M.; Mannisto, S.; Di Pietro, R.; Iacone, A.; Zauli, G. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004, 103, 517-522. (Pubitemid 38140081)
20. Milani, D.; Zauli G.; Rimondi, E.; Celeghini, C.; Marmiroli, S.; Narducci, P.; Capitani, S.; Secchiero, P. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates prosurvival and pro-apoptotic pathways in SK-N-MC neuronal cells. J. Neurochem. 2003, 86, 126-135. (Pubitemid 36753853)
21. Zenz, T.; Krober, A.; Scherer, K., Habe, S.; Buhler, A.; Benner, A.; Denzel, T.; Winkler, D.; Edelmann, J.; Schwanen, C.; Dohner, H.; Stilgenbauer, S. Mono-allelic TP53 inactivation is associated with poor prognosis in CLL: Results from a detailed genetic characterization with long term follow-up. Blood 2008, 112, 3322-3329.
22. Broberg, P. Statistical methods for ranking differentially expressed genes. Genome Biol. 2003, 4, R41.
23. Bomben, R.; Dal Bo, M.; Capello, D.; Benedetti, D.; Marconi, D.; Zucchetto, A.; Forconi, F.; Maffei, R.; Ghia, E. M.; Laurenti, L.; Bulian, P.; Del Principe, M. L.; Palermo, G.; Thorsélius, M.; Degan, M.; Campanini, R.; Guarini, A.; Del Poeta, G.; Rosenquist, R.; Efremov, D. G.; Marasca, R.; Foà, R.; Gaidano, G.; Gattei, V. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicentric study. Blood 2007, 109, 2989-2998. (Pubitemid 46482099)
24. Draghici, S.; Khatri, P.; Bhavsar, P.; Shah, A.; Krawetz, S. A.; Tainsky, M. A. Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res. 2003, 31, 3775-3781. (Pubitemid 37442244)
25. Zhang, B.; Schmoyer, D.; Kirov, S.; Snoddy, J. GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 2004, 5, 16.
26. Secchiero, P.; Zerbinati, C.; di Iasio, M. G.; Melloni, E.; Tiribelli, M.; Grill, V.; Zauli, G. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr. Drug. Metab. 2007, 8, 395-403. (Pubitemid 46780067)
27. Toledo, F.; Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6, 909-923. (Pubitemid 44862676)
28. Meulmeester, E.; Jochemsen, A. G. p53: a guide to apoptosis. Curr. Cancer Drug. Targets 2008, 8, 87-97. (Pubitemid 351347244)
29. Secchiero, P.; di Iasio, M. G.; Gonelli, A.; Zauli, G. The MDM2 inhibitor Nutlins a san innovative therapeutic tool for the treatment of hematological malignancies. Curr. Pharm. Des. 2008, 14, 2100-2110.
30. Mihara, M.; Erster, S.; Zaika, A.; Petrenko, O.; Chittenden, T.; Pancoska, P.; Moll, U. M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell. 2003, 11, 577-590. (Pubitemid 36385115)
31. Arima, Y.; Nitta, M.; Kuninaka, S.; Zhang, D.; Fujiwara, T.; Taya, Y.; Nakao, M.; Saya, H. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J. Biol. Chem. 2005, 280, 19166-19176. (Pubitemid 41379623)
32. Steele, A. J.; Prentice, A. G.; Hoffbrand, A. V.; Yogashangary, B.C.; Hart, S. M.; Nacheva, E. P.; Howard-Reeves, J. D.; Duke, V. M.; Kottaridis, P. D.; Cwynarski, K.; Vassilev, L. T.; Wickremasinghe, R. G. p53-mediated apoptosis in CLL cells: evidence for a transcription-independent mechanism. Blood 2008, 112, 3827-3834.
33. Tovar, C.; Rosinski, J.; Filipovic, Z.; Higgins, B.; Kolinsky, K.; Hilton, H.; Zhao, X.; Vu, B. T.; Qing, W.; Packman, K.; Myklebost, O.; Heimbrook, D. C.; Vassilev, L. T. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 2006, 103, 1888-1893. (Pubitemid 43228788)
34. Pepper, C.; Hoy, T.; Bentley, D. P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br. J. Cancer 1997, 76, 935-938. (Pubitemid 27401947)
35. Pepper, C.; Lin, T. T.; Pratt, G.; Hewamana, S.; Brennan, P.; Hiller, L.; Hills, R.; Ward, R.; Starczynski, J.; Austen, B.; Hooper, L.; Stankovic, T.; Fegan, C. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008, 112, 3807-3817.
36. Froment, P.; Dupont, J.; Christophe-Marine, J. Mdm2 exerts proapoptotic activities by antagonizing insulin-like growth factor-I-mediated survival. Cell Cycle 2008, 7, 3098-3103.
37. Hu, B.; Gilkes, D. M.; Farooqi, B.; Sebti, S. M.; Chen, J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J. Biol. Chem. 2006, 281, 33030-33035. (Pubitemid 46036685)
38. Patton, J. T.; Mayo, L. D.; Singhi, A. D.; Gudkov, A. V.; Stark, G. R.; Jackson, M. W. Levels of HdmX epression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006, 66, 3169-3176.
39. Wade, M.; Wong, E. T.; Tang, M.; Stommel, J. M.; Wahl, G. M. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 2006, 281, 33036-33044. (Pubitemid 46036686)